EVALUATING THE CLINICAL, SOCIOECONOMIC, AND ENVIRONMENTAL IMPACT OF GUIDELINE-DIRECTED THERAPY IN JAPAN: AN IMPACT CKD ANALYSIS

 

Certificate Output Instructions

For best output, select "Paper Size" as "A4" and "Margin" as "0" or "None".

To save or print to PDF, please select Print Destination > Save as PDF, enable Background Graphics under "More Settings", then click "Save".

 

 

Certificate Background

   

Presented the abstract " "
(Abstract co-author(s):  )

 

 

  Back
E-Poster Presentation

During the congress, E-Posters will be accessible to all participants on the congress website 24/7, as well as in the E-poster stations in the congress center. 

Preparing your E-Poster

Please review the E-Poster format requirements carefully when preparing your E-Poster. Should your E-Poster not meet the mentioned requirements, it may not be displayed as described above.

​E-Poster Submission Deadline

Please prepare and upload your E-Poster no later than March 14, 2026 11.59PM CET. After this date, you will no longer be able to prepare and upload your E-poster and it will not be displayed and accessible on the congress website.​

E-Poster Format Requirements
  • PDF file
  • Layout: Portrait (vertical orientation)
  • One page only (Dim A4: 210 x 297mm or PPT)
  • E-Poster can be prepared in PowerPoint (one (1) PowerPoint slide) but must be saved and submitted as PDF file.
  • File Size: Maximum file size is 2 Megabytes (2 MB)
  • No hyperlinks, animated images, animations, and slide transitions
  • Language: English
  • Include your abstract number
  • E-posters can include QR codes, tables and photos
https://storage.unitedwebnetwork.com/files/1099/f35de1acae514704ad2cb3d6daf6e3b0.pdf
EVALUATING THE CLINICAL, SOCIOECONOMIC, AND ENVIRONMENTAL IMPACT OF GUIDELINE-DIRECTED THERAPY IN JAPAN: AN IMPACT CKD ANALYSIS

Please follow the instructions below to input your abstract title.

Abstract titles should be brief and reflect the content of the abstract.

  • The title will not be accepted if it exceeds 25 words.
  • Type in CAPITAL LETTERS.
  • Lowercase may be used for abbreviations only, for example, mRNA.
Kei
Nagai
Kei Nagai knagai@md.tsukuba.ac.jp University of Tsukuba Department of Nephrology Ibaraki Japan *
Shingo Shoji shingo.shoji@astrazeneca.com AstraZeneca K.K. Evidence and Observational Research, Medical Osaka Japan -
Noriharu Chishima Noriharu.Chishima@astrazeneca.com AstraZeneca K.K. Cardiovascular, Renal and Metabolism, BioPharmaceuticals Medical Osaka Japan -
Stacey Priest stacey.priest@eversana.com EVERSANA Value & Evidence Services Burlington Canada -
Keisuke Nansai nansai.keisuke@nies.go.jp National Institute for Environmental Studies Material Cycles Division Ibaraki Japan -
Kouichi Tamura tamukou@yokohama-cu.ac.jp Yokohama City University Graduate School of Medicine Department of Medical Science and Cardiorenal Medicine Kanagawa Japan -